Fast Track Designation highlights potential of amezalpat to address unmet need for patients with HCC Amezalpat builds ...

Amezalpat received fast track designation from the FDA for the treatment of patients with hepatocellular carcinoma.

Amezalpat is an investigational oral, small molecule, selective peroxisome proliferator-activated receptor-alpha antagonist.

The FDA has granted fast track designation to amezalpat for the treatment of patients with hepatocellular carcinoma.

Tempest Therapeutics (TPST) announced that the U.S. Food and Drug Administration, FDA, has granted Fast Track Designation, FTD, to amezalpat, ...

Amezalpat has been granted FDA fast track designation as treatment for patients with hepatocellular carcinoma.

On January 7, 2025, the FDA granted priority review to the new drug application for sunvozertinib (DZD9008), an oral EGFR ...

The stock options will vest over a four-ye Company welcomes additional late-stage expertise as it prepares for amezalpat pivotal studyBRISBANE, Calif., Sept. 18, 2024 (GLOBE NEWSWIRE ...

For unresectable or metastatic liver cancer, the TPST-1120-301 trial of amezalpat combination therapy has received a “Study May Proceed” letter from the FDA. From “Boy Meets World” actress Danielle ...

FORT WAYNE, Ind., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Vera Bradley (NASDAQ: VRA) (the "Company”) today announced the appointment of Andrew Meslow, former CEO of L Brands and Bath and Body Works, to the ...